Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bank of Montreal (BMO) vs Incyte Corporation (INCY) Price & Performance

Bank of MontrealTrade
Incyte CorporationTrade

Price performance (Past 24H)

Key statistics

Bank of Montreal vs Incyte Corporation — how do they compare? Bank of Montreal trades at $182.04 (market cap $126.83B), while Incyte Corporation trades at $120.45 (market cap $24.54B). The key difference: Bank of Montreal is far larger — about 5.2× Incyte Corporation's market cap, and Bank of Montreal pays a 2.69% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.

BMOINCY
Market Cap
$126.83B$24.54B
Sector
FinancialsHealth
52-Week High
$183.65$129.93
52-Week Low
$112.54$81.61
Dividend Yield
2.69%
Enterprise Value
$20.04B

Returns comparison

Trailing returns across standard periods

About Bank of Montreal

Bank of Montreal is a diversified financial-services provider based in North America, operating four business segments: Canadian personal and commercial banking, U.S. P&C banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the U.S.

Read more on BMO

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Read more on INCY